Ibutilide

Also Known As: Ibutilide, Corvert

Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period (physiology) of myocardial cells. Because of its Class III antiarrhythmic activity, there should not be concomitant administration of Class Ia and Class III agents.

Ibutilide is marketed as Corvert by Pfizer. Administration resulted in successful heart rhythm control in 31-44% of patients within 90 minutes, with sustained polymorphic ventricular tachycardia in 0.9-2.5% of patients. It appears to show better results in atrial flutter as compared to atrial fibrillation.

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:

0 = No improvement or Worse
1 = Slight improvement
2 = Moderate Improvement
3 = Significant Improvement
4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Ibutilide to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.